EVOKE PHARMA INC (EVOK) Stock Price, Quote, News and Overview
NASDAQ:EVOK - Nasdaq - US30049G3020 - Common Stock - Currency: USD
EVOK Quote, Performance and Key Statistics
3.0732
+0.12 (+4.18%)
The current stock price of EVOK is 3.0732 USD. In the past month the price decreased by -8.67%. In the past year, price decreased by -56.1%.
EVOK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 56.4 | 735.46B | ||
| JNJ | JOHNSON & JOHNSON | 15.5 | 374.79B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 20.88 | 333.12B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.23 | 233.55B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.66 | 227.29B | ||
| MRK | MERCK & CO. INC. | 10.15 | 198.62B | ||
| PFE | PFIZER INC | 7.51 | 136.99B | ||
| SNY | SANOFI-ADR | 11.24 | 121.70B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.68 | 99.81B | ||
| GSK | GSK PLC-SPON ADR | 9.24 | 83.53B | ||
| ZTS | ZOETIS INC | 27.55 | 73.85B | ||
| HLN | HALEON PLC-ADR | 22.32 | 49.20B |
Related stock screener links
About EVOK
Company Profile
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 3 full-time employees. The company went IPO on 2013-09-25. The firm is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The firm operates through the development and commercialization of pharmaceutical products. The company is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The company developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. The company has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
Company Info
EVOKE PHARMA INC
420 Stevens Avenue, Suite 230
Solana Beach CALIFORNIA 92075 US
CEO: David A. Gonyer
Employees: 3
Phone: 18583451494
EVOKE PHARMA INC / EVOK FAQ
What is the stock price of EVOKE PHARMA INC today?
The current stock price of EVOK is 3.0732 USD. The price increased by 4.18% in the last trading session.
What is the ticker symbol for EVOKE PHARMA INC stock?
The exchange symbol of EVOKE PHARMA INC is EVOK and it is listed on the Nasdaq exchange.
On which exchange is EVOK stock listed?
EVOK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EVOKE PHARMA INC stock?
7 analysts have analysed EVOK and the average price target is 18.36 USD. This implies a price increase of 497.42% is expected in the next year compared to the current price of 3.0732. Check the EVOKE PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EVOKE PHARMA INC worth?
EVOKE PHARMA INC (EVOK) has a market capitalization of 4.58M USD. This makes EVOK a Nano Cap stock.
How many employees does EVOKE PHARMA INC have?
EVOKE PHARMA INC (EVOK) currently has 3 employees.
What are the support and resistance levels for EVOKE PHARMA INC (EVOK) stock?
EVOKE PHARMA INC (EVOK) has a support level at 2.94 and a resistance level at 3.6. Check the full technical report for a detailed analysis of EVOK support and resistance levels.
Is EVOKE PHARMA INC (EVOK) expected to grow?
The Revenue of EVOKE PHARMA INC (EVOK) is expected to grow by 58.22% in the next year. Check the estimates tab for more information on the EVOK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EVOKE PHARMA INC (EVOK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EVOK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EVOK, evaluating the profitability, health, valuation and growth aspects
- EVOKE PHARMA INC (EVOK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EVOKE PHARMA INC (EVOK) Sales and EPS estimates to see what analysts future expectations are.
- EVOKE PHARMA INC (EVOK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EVOKE PHARMA INC (EVOK) Insider and Institutional Ownership to learn about the owners and their transactions.
- EVOKE PHARMA INC (EVOK) Stock Chart to make your own analysis
- EVOKE PHARMA INC (EVOK) Latest news and press-releases to stay up to date.
Does EVOKE PHARMA INC (EVOK) stock pay dividends?
EVOK does not pay a dividend.
When does EVOKE PHARMA INC (EVOK) report earnings?
EVOKE PHARMA INC (EVOK) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of EVOKE PHARMA INC (EVOK)?
EVOKE PHARMA INC (EVOK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.01).
What is the Short Interest ratio of EVOKE PHARMA INC (EVOK) stock?
The outstanding short interest for EVOKE PHARMA INC (EVOK) is 1.86% of its float. Check the ownership tab for more information on the EVOK short interest.
EVOK Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to EVOK. When comparing the yearly performance of all stocks, EVOK is a bad performer in the overall market: 93.58% of all stocks are doing better.
EVOK Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EVOK. EVOK has a bad profitability rating. Also its financial health evaluation is rather negative.
EVOK Financial Highlights
Over the last trailing twelve months EVOK reported a non-GAAP Earnings per Share(EPS) of -3.01. The EPS increased by 86.29% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.01% | ||
| ROE | -86.94% | ||
| Debt/Equity | 0.86 |
EVOK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to EVOK. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 77.31% and a revenue growth 58.22% for EVOK